AKT1 and neoplasm: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, achieves triple anti-tumor effects by blocking the PI3K-AKT-mTOR signaling pathway: inhibiting tumor cell growth, reducing tumor cell nutrient metabolism, and affecting tumor angiogenesis (Menzel et al., 2023; Park et al., 2023).